Issue navigation
Volume 60, Issue 2, February 2021
EDITORIALS
The role of sleep in the activity of lupus erythematosus: an overview of this possible relationship
Rheumatology, Volume 60, Issue 2, February 2021, Pages 483–486, https://doi.org/10.1093/rheumatology/keaa744
The efficacy of a nurse-led interventional program to improve the health of patients with axial spondyloarthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 487–488, https://doi.org/10.1093/rheumatology/keaa639
Rituximab for the treatment of systemic sclerosis-interstitial lung disease
Rheumatology, Volume 60, Issue 2, February 2021, Pages 489–491, https://doi.org/10.1093/rheumatology/keaa675
Shifting knowledge and attitudes about biosimilars among rheumatologists
Rheumatology, Volume 60, Issue 2, February 2021, Pages 492–493, https://doi.org/10.1093/rheumatology/keaa760
REVIEW ARTICLES
Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family
Rheumatology, Volume 60, Issue 2, February 2021, Pages 494–506, https://doi.org/10.1093/rheumatology/keaa609
Potential efficacy of dendritic cell immunomodulation in the treatment of osteoarthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 507–517, https://doi.org/10.1093/rheumatology/keaa745
Arthroscopy in rheumatology: where have we been? Where might we go?
Rheumatology, Volume 60, Issue 2, February 2021, Pages 518–528, https://doi.org/10.1093/rheumatology/keaa560
Osteosarcopenia: where osteoporosis and sarcopenia collide
Rheumatology, Volume 60, Issue 2, February 2021, Pages 529–537, https://doi.org/10.1093/rheumatology/keaa755
SYSTEMATIC REVIEW AND META-ANALYSIS
Vitamin D receptor gene polymorphisms and osteoarthritis: a meta-analysis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 538–548, https://doi.org/10.1093/rheumatology/keaa644
Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 549–556, https://doi.org/10.1093/rheumatology/keaa534
Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 557–567, https://doi.org/10.1093/rheumatology/keaa550
Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 568–587, https://doi.org/10.1093/rheumatology/keaa595
CLINICAL SCIENCE
Lymphopenia in primary Sjögren’s syndrome is associated with premature aging of naïve CD4+ T cells
Rheumatology, Volume 60, Issue 2, February 2021, Pages 588–597, https://doi.org/10.1093/rheumatology/keaa105
Metabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus
Rheumatology, Volume 60, Issue 2, February 2021, Pages 598–606, https://doi.org/10.1093/rheumatology/keaa126
Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline?
Rheumatology, Volume 60, Issue 2, February 2021, Pages 607–616, https://doi.org/10.1093/rheumatology/keaa165
Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes
Rheumatology, Volume 60, Issue 2, February 2021, Pages 617–628, https://doi.org/10.1093/rheumatology/keaa215
Role of stress in the development of rheumatoid arthritis: a case–control study
Rheumatology, Volume 60, Issue 2, February 2021, Pages 629–637, https://doi.org/10.1093/rheumatology/keaa216
Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable
Rheumatology, Volume 60, Issue 2, February 2021, Pages 638–648, https://doi.org/10.1093/rheumatology/keaa241
Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 649–657, https://doi.org/10.1093/rheumatology/keaa228
Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines)
Rheumatology, Volume 60, Issue 2, February 2021, Pages 658–666, https://doi.org/10.1093/rheumatology/keaa219
Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study
Rheumatology, Volume 60, Issue 2, February 2021, Pages 667–674, https://doi.org/10.1093/rheumatology/keaa258
Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS
Rheumatology, Volume 60, Issue 2, February 2021, Pages 675–681, https://doi.org/10.1093/rheumatology/keaa257
CLINICAL SCIENCE
Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 682–691, https://doi.org/10.1093/rheumatology/keaa259
CLINICAL SCIENCE
Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies
Rheumatology, Volume 60, Issue 2, February 2021, Pages 692–698, https://doi.org/10.1093/rheumatology/keaa337
Muscle biopsy in anti-neutrophil cytoplasmic antibody–associated vasculitis: diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count
Rheumatology, Volume 60, Issue 2, February 2021, Pages 699–707, https://doi.org/10.1093/rheumatology/keaa233
Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients
Rheumatology, Volume 60, Issue 2, February 2021, Pages 708–716, https://doi.org/10.1093/rheumatology/keaa316
Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI)
Rheumatology, Volume 60, Issue 2, February 2021, Pages 717–727, https://doi.org/10.1093/rheumatology/keaa343
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients
Rheumatology, Volume 60, Issue 2, February 2021, Pages 728–736, https://doi.org/10.1093/rheumatology/keaa355
Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 737–750, https://doi.org/10.1093/rheumatology/keaa370
Clinical Science
Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 751–761, https://doi.org/10.1093/rheumatology/keaa405
CLINICAL SCIENCE
Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities
Rheumatology, Volume 60, Issue 2, February 2021, Pages 762–766, https://doi.org/10.1093/rheumatology/keaa407
Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study
Rheumatology, Volume 60, Issue 2, February 2021, Pages 767–772, https://doi.org/10.1093/rheumatology/keaa411
Which factors predict discordance between a patient and physician on a gout flare?
Rheumatology, Volume 60, Issue 2, February 2021, Pages 773–779, https://doi.org/10.1093/rheumatology/keaa413
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
Rheumatology, Volume 60, Issue 2, February 2021, Pages 780–784, https://doi.org/10.1093/rheumatology/keaa399
Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk
Rheumatology, Volume 60, Issue 2, February 2021, Pages 785–801, https://doi.org/10.1093/rheumatology/keaa270
External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort
Rheumatology, Volume 60, Issue 2, February 2021, Pages 802–808, https://doi.org/10.1093/rheumatology/keaa274
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype
Rheumatology, Volume 60, Issue 2, February 2021, Pages 809–819, https://doi.org/10.1093/rheumatology/keaa330
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Rheumatology, Volume 60, Issue 2, February 2021, Pages 820–828, https://doi.org/10.1093/rheumatology/keaa393
Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America
Rheumatology, Volume 60, Issue 2, February 2021, Pages 829–836, https://doi.org/10.1093/rheumatology/keaa436
Genetic and clinical basis for two distinct subtypes of primary Sjögren’s syndrome
Rheumatology, Volume 60, Issue 2, February 2021, Pages 837–848, https://doi.org/10.1093/rheumatology/keaa367
High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 849–854, https://doi.org/10.1093/rheumatology/keaa332
Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017
Rheumatology, Volume 60, Issue 2, February 2021, Pages 855–865, https://doi.org/10.1093/rheumatology/keaa315
Low-density lipoprotein from active SLE patients is more atherogenic to endothelial cells than low-density lipoprotein from the same patients during remission
Rheumatology, Volume 60, Issue 2, February 2021, Pages 866–871, https://doi.org/10.1093/rheumatology/keaa380
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)
Rheumatology, Volume 60, Issue 2, February 2021, Pages 872–880, https://doi.org/10.1093/rheumatology/keaa401
Long-term outcome after perineural injection with 5% dextrose for carpal tunnel syndrome: a retrospective follow-up study
Rheumatology, Volume 60, Issue 2, February 2021, Pages 881–887, https://doi.org/10.1093/rheumatology/keaa361
Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA)
Rheumatology, Volume 60, Issue 2, February 2021, Pages 888–895, https://doi.org/10.1093/rheumatology/keaa480
US rheumatologists’ beliefs and knowledge about biosimilars: a survey
Rheumatology, Volume 60, Issue 2, February 2021, Pages 896–901, https://doi.org/10.1093/rheumatology/keaa502
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population
Rheumatology, Volume 60, Issue 2, February 2021, Pages 902–906, https://doi.org/10.1093/rheumatology/keaa694
COVID-19 and myositis – unique challenges for patients
Rheumatology, Volume 60, Issue 2, February 2021, Pages 907–910, https://doi.org/10.1093/rheumatology/keaa610
Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
Rheumatology, Volume 60, Issue 2, February 2021, Pages 911–917, https://doi.org/10.1093/rheumatology/keaa652
BASIC AND TRANSLATIONAL SCIENCE
Dorsal horn disinhibition and movement-induced behaviour in a rat model of inflammatory arthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 918–928, https://doi.org/10.1093/rheumatology/keaa396
Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 929–939, https://doi.org/10.1093/rheumatology/keaa447
Circulating adiponectin levels and systemic lupus erythematosus: a two-sample Mendelian randomization study
Rheumatology, Volume 60, Issue 2, February 2021, Pages 940–946, https://doi.org/10.1093/rheumatology/keaa506
TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20
Rheumatology, Volume 60, Issue 2, February 2021, Pages 947–957, https://doi.org/10.1093/rheumatology/keaa551
Genetic diversity of Staphylococcus aureus influences disease phenotype of systemic lupus erythematosus
Rheumatology, Volume 60, Issue 2, February 2021, Pages 958–966, https://doi.org/10.1093/rheumatology/keaa519
Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker
Rheumatology, Volume 60, Issue 2, February 2021, Pages 967–975, https://doi.org/10.1093/rheumatology/keaa648
LETTERS TO THE EDITOR
OTHERS
Increased falls risk in people with psoriatic arthritis-related foot problems: a novel finding
Rheumatology, Volume 60, Issue 2, February 2021, Pages 976–977, https://doi.org/10.1093/rheumatology/keaa654
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic
Rheumatology, Volume 60, Issue 2, February 2021, Pages 977–979, https://doi.org/10.1093/rheumatology/keaa653
Validation of a Dutch diagnostic rule for gout without joint fluid analysis in patients hospitalized for acute monoarthritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 979–981, https://doi.org/10.1093/rheumatology/keaa664
CLINICAL VIGNETTES
Severe deformity in long-term SAPHO syndrome
Rheumatology, Volume 60, Issue 2, February 2021, Pages 982–983, https://doi.org/10.1093/rheumatology/keaa307
Focal hamstring muscle oedema and atrophy post-anterior cruciate ligament reconstruction mimicking focal myositis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 984–985, https://doi.org/10.1093/rheumatology/keaa397
Coated aorta in Erdheim–Chester disease
Rheumatology, Volume 60, Issue 2, February 2021, Pages 986–987, https://doi.org/10.1093/rheumatology/keaa430
Chilblain lupus erythematosus associated with systemic and discoid lupus erythematosus
Rheumatology, Volume 60, Issue 2, February 2021, Page 988, https://doi.org/10.1093/rheumatology/keaa385
Inclusion body myositis and muscular granulomas – a rare finding
Rheumatology, Volume 60, Issue 2, February 2021, Pages 989–990, https://doi.org/10.1093/rheumatology/keaa344
Sacroiliitis in sarcoidosis mimicking ankylosing spondylitis
Rheumatology, Volume 60, Issue 2, February 2021, Pages 991–992, https://doi.org/10.1093/rheumatology/keaa445
IgA vasculitis presenting as recurrent hemopericardium
Rheumatology, Volume 60, Issue 2, February 2021, Pages 993–994, https://doi.org/10.1093/rheumatology/keaa390
Cervical spine involvement in ankylosing spondylitis mimicking Eagle’s syndrome
Rheumatology, Volume 60, Issue 2, February 2021, Pages 995–996, https://doi.org/10.1093/rheumatology/keaa552
Editor’s Acknowledgement
Editor’s Acknowledgement
Rheumatology, Volume 60, Issue 2, February 2021, Pages 997–1005, https://doi.org/10.1093/rheumatology/keaa868
PUBLISHED ONLINE ONLY
CASE REPORTS
Systemic lupus erythematosus onset in patient receiving anti-PD1 treatment with pembrolizumab: a case report
Rheumatology, Volume 60, Issue 2, February 2021, Pages e39–e40, https://doi.org/10.1093/rheumatology/keaa389
Relapsing polychondritis of the nose and lower respiratory tract
Rheumatology, Volume 60, Issue 2, February 2021, Pages e41–e43, https://doi.org/10.1093/rheumatology/keaa400
Successful treatment of spondyloenchondrodysplasia with baricitinib
Rheumatology, Volume 60, Issue 2, February 2021, Pages e44–e46, https://doi.org/10.1093/rheumatology/keaa356
Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports
Rheumatology, Volume 60, Issue 2, February 2021, Pages e47–e49, https://doi.org/10.1093/rheumatology/keaa287
Pathologically confirmed oesophageal involvement in idiopathic multicentric Castleman disease mimicking early oesophageal cancer
Rheumatology, Volume 60, Issue 2, February 2021, Pages e50–e52, https://doi.org/10.1093/rheumatology/keaa431
Myeloperoxidase positivity in giant cell arteritis presenting with fever of unknown origin
Rheumatology, Volume 60, Issue 2, February 2021, Pages e53–e55, https://doi.org/10.1093/rheumatology/keaa442
Catch the thief by its marks: inverse Gottron papules, interstitial lung disease, anti MDA-5 antibody positivity in juvenile dermatomyositis
Rheumatology, Volume 60, Issue 2, February 2021, Pages e56–e58, https://doi.org/10.1093/rheumatology/keaa433
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma
Rheumatology, Volume 60, Issue 2, February 2021, Pages e59–e60, https://doi.org/10.1093/rheumatology/keaa572
Focal small bowel thrombotic microvascular injury in COVID-19 mediated by the lectin complement pathway masquerading as lupus enteritis
Rheumatology, Volume 60, Issue 2, February 2021, Pages e61–e63, https://doi.org/10.1093/rheumatology/keaa627
IgG4-related disease of the mitral and aortic valves presenting as rapid, recurrent prosthetic valve failure
Rheumatology, Volume 60, Issue 2, February 2021, Pages e64–e65, https://doi.org/10.1093/rheumatology/keaa536
MATTERS ARISING
Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference
Rheumatology, Volume 60, Issue 2, February 2021, Page e66, https://doi.org/10.1093/rheumatology/keaa764
Comment on: Diagnostic accuracy of ultrasound for detecting large vessel giant cell arteritis using FDG PET/CT as the reference: reply
Rheumatology, Volume 60, Issue 2, February 2021, Pages e67–e68, https://doi.org/10.1093/rheumatology/keaa765
Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable
Rheumatology, Volume 60, Issue 2, February 2021, Pages e69–e70, https://doi.org/10.1093/rheumatology/keaa690
Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply
Rheumatology, Volume 60, Issue 2, February 2021, Pages e71–e72, https://doi.org/10.1093/rheumatology/keaa688
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease
Rheumatology, Volume 60, Issue 2, February 2021, Pages e73–e75, https://doi.org/10.1093/rheumatology/keaa753
Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply
Rheumatology, Volume 60, Issue 2, February 2021, Pages e76–e77, https://doi.org/10.1093/rheumatology/keaa754
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma
Rheumatology, Volume 60, Issue 2, February 2021, Page e78, https://doi.org/10.1093/rheumatology/keaa798
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply
Rheumatology, Volume 60, Issue 2, February 2021, Pages e79–e80, https://doi.org/10.1093/rheumatology/keaa799
